Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 16/20 | 1.00 |
| ▸ | SLC2A4 | P14672 | 3/20 | 0.77 |
| ▸ | SLC2A8 | Q9NY64 | 1/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.45 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20339753 | 0.88 | SLC2A1 (1.00) | SLC2A1SLC2A4SLC2A8LPAR1LPAR5 | |
| SCHEMBL21500123 | 0.87 | SLC2A4 (1.00) | SLC2A1SLC2A4SLC2A8LPAR1LPAR5 | |
| SCHEMBL20339783 | 0.86 | SLC2A1 (1.00) | SLC2A1SLC2A4SLC2A8LPAR1LPAR5 | |
| SCHEMBL20339799 | 0.85 | SLC2A1 (1.00) | SLC2A1SLC2A4SLC2A8LPAR1LPAR5 | |
| SCHEMBL20339353 | 0.84 | SLC2A1 (1.00) | SLC2A1SLC2A4SLC2A8LPAR1LPAR5 | |
| SCHEMBL20339305 | 0.81 | SLC2A1 (1.00) | SLC2A1SLC2A4SLC2A8LPAR1LPAR5 | |
| SCHEMBL20339757 | 0.81 | SLC2A1 (1.00) | SLC2A1SLC2A4SLC2A8LPAR1LPAR5 | |
| SCHEMBL23269336 | 0.79 | SLC2A1 (0.74) | SLC2A1SLC2A4SLC2A8KDM4EALDH1A1 | |
| SCHEMBL20338615 | 0.77 | SLC2A1 (1.00) | SLC2A1SLC2A4SLC2A8 | |
| SCHEMBL20339979 | 0.77 | SLC2A1 (1.00) | SLC2A1SLC2A4SLC2A8LPAR1LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190321345-A1 | GLUT4 Selective Inhibitors for Cancer Therapy | UNIV EMORY (US) | 2019-10-24 | — | — | US | disclosed |
| WO-2018125968-A1 | GLUT4 SELECTIVE INHIBITORS FOR CANCER THERAPY | EMORY UNIVERSITY (US) | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190321345-A1 | GLUT4 Selective Inhibitors for Cancer Therapy | SLC2A4, SLC2A1, SLC2A2 | SLC2A1 2/4885SLC2A4 1/4885SLC2A8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.